What is the 13F Pro Quality Score for MYO?

13F Pro ranks MYOMO, INC. (MYO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MYO's current score at https://13fpro.ai/research/MYO (free sign-up required for the full ranking).

Which hedge funds own the most MYO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MYO include Rosalind Advisors,, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MYO as soon as new 13F filings post.

Where does 13F Pro source MYO data?

All MYOMO, INC. fundamentals and ownership data come directly from SEC EDGAR. MYOMO, INC. files with the SEC under CIK 1369290. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MYO in?

MYOMO, INC. (MYO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MYO research updated on 13F Pro?

MYO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MYOMO, INC.(MYO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1369290 MYO stock profile & AI dashboard →

13F Pro Quality Score

27.9/100

Rank #2,459 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.8/100

Profitability

11.7/100

Balance Sheet

5.3/100

Earnings Quality

30.0/100

Free Cash Flow

9.5/100

Institutional Flow

16.6/100

Revenue Scale

9.1/100

Dilution Risk

25.5/100

MYO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MYOMO, INC. (MYO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MYO at 27.9/100 on a 32-signal composite quality model, placing it at rank #2,459 of 2,879 stocks — the bottom half of the AI-ranked universe. MYO scores in the top quartile across revenue growth (91.8). Areas of concern include balance sheet strength (5.3) and revenue scale (9.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MYOMO, INC. reports quarterly revenue of $10.1M, net income of $-3.0M, an operating margin of -31.2%. Top institutional holders of MYO by reported 13-F value include Rosalind Advisors,, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MYO trades on the NYSE exchange and files with the SEC under CIK 1369290. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MYO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MYOMO, INC. directly from SEC EDGAR. MYOMO, INC.'s 13F Pro composite quality score has ranged between 27 and 35 since 2025, currently 27.9 — a stable long-term trajectory across 14 quarterly and live scoring snapshots.

Revenue

Q1 2026

$10.1M

Net Income

Q1 2026

$-3.0M

Free Cash Flow

Q1 2026

$-2.5M

Operating Margin

Q1 2026

-31.2%

D/E Ratio

Q1 2026

1.52

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+69.2% YoY

$32.6MFY 2024

FY21 $13.9MFY22 $15.6MFY23 $19.2MFY24 $32.6M

Net Income

+23.5% YoY

$-6.2MFY 2024

FY21 $-10.4MFY22 $-10.7MFY23 $-8.1MFY24 $-6.2M

Operating Income

+24.6% YoY

$-6.2MFY 2024

FY21 $-10.3MFY22 $-10.7MFY23 $-8.2MFY24 $-6.2M

EPS (Diluted)

+42.9% YoY

$-0.16FY 2024

FY21 $-1.89FY22 $-1.52FY23 $-0.28FY24 $-0.16

Total Assets

+189.7% YoY

$42.2MFY 2024

FY21 $20.1MFY22 $10.2MFY23 $14.6MFY24 $42.2M

Total Debt

$11.2MFY 2024

FY21 —FY22 —FY23 —FY24 $11.2M

Op. Cash Flow

+46.7% YoY

$-3.3MFY 2024

FY21 $-9.5MFY22 $-10.2MFY23 $-6.2MFY24 $-3.3M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$32.6M +69.2%	$19.2M +23.7%	$15.6M +12.3%	$13.9M +82.7%	$7.6M +97.6%	$3.8M
Net Income	$-6.2M +23.5%	$-8.1M +24.4%	$-10.7M -3.4%	$-10.4M +10.3%	$-11.6M -7.9%	$-10.7M
Operating Income	$-6.2M +24.6%	$-8.2M +22.9%	$-10.7M -3.9%	$-10.3M +2.2%	$-10.5M +2.7%	$-10.8M
EPS (Diluted)	$-0.16 +42.9%	$-0.28 +81.6%	$-1.52 +19.6%	$-1.89	—	—
Total Assets	$42.2M +189.7%	$14.6M +43.5%	$10.2M -49.4%	$20.1M +36.6%	$14.7M +122.9%	$6.6M
Total Debt	$11.2M	—	—	—	—	$2.7M
Operating Cash Flow	$-3.3M +46.7%	$-6.2M +39.7%	$-10.2M -7.2%	$-9.5M -5.7%	$-9.0M +12.7%	$-10.3M

AI Insight: MYO Financial Trends

Myomo faces persistent unprofitability and weakening balance sheet despite stabilizing revenue at ~$10M quarterly.

• Revenue flat at $10–11M over last five quarters; no growth trajectory despite Q4 2024 spike to $12M.

• Operating cash flow improving modestly: −$9M in Q2 2025 to −$1M in Q4 2025, then −$2M in Q1 2026.

• Equity contracted 64% from $25M (Q4 2024) to $9M (Q1 2026); debt jumped from $0M to $14M over same period.

⚠ Operating losses persist: −$3M to −$5M quarterly with no path to profitability visible in recent quarters.

⚠ Leverage spike: debt-to-equity ratio swung from near-zero to 1.6x in Q1 2026 amid equity erosion.

AI Insight: MYO Ratio Trends

MYO remains deeply unprofitable with deteriorating margins; Q1 2026 shows no path to sustainability.

• Operating margin worsened to -31.2% in Q1 2026 from -24.4% in Q4 2025, reversing four quarters of gradual improvement.

• ROE collapsed to -133.7% in Q1 2026, matching Q4 2025 lows. ROIC deteriorated to -55.7% from -43.4% in Q3 2025.

• Leverage spiked to 1.52 D/E in Q1 2026, matching TTM peak, despite minimal equity cushion to absorb continued losses.

⚠ Q4 2025 marked the only near-breakeven quarter (-2.0% OpMargin); regression in Q1 2026 signals operational deterioration, not seasonal dip.

⚠ Negative ROIC persists across all periods; no evidence of capital deployment creating shareholder value or approaching profitability.

Get alerted when MYO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MYOMO, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MYO

Rosalind Advisors, Inc.
$2.6M3,847,272 sh
BlackRock, Inc.
$1.1M1,688,390 sh
VANGUARD CAPITAL MANAGEMENT LLC
$773.6K1,144,324 sh
GEODE CAPITAL MANAGEMENT, LLC
$580.3K858,799 sh
LEUCADIA NATIONAL CORP
$475.8K704,275 sh
Clearstead Advisors, LLC
$287.5K425,600 sh
STATE STREET CORP
$258.9K383,191 sh
Nuveen, LLC
$250.2K370,325 sh
AQR CAPITAL MANAGEMENT LLC
$215.5K318,951 sh
UBS Group AG
$210.7K311,721 sh

Fund	Value	Shares
Rosalind Advisors, Inc.	$2.6M	3,847,272
BlackRock, Inc.	$1.1M	1,688,390
VANGUARD CAPITAL MANAGEMENT LLC	$773.6K	1,144,324
GEODE CAPITAL MANAGEMENT, LLC	$580.3K	858,799
LEUCADIA NATIONAL CORP	$475.8K	704,275
Clearstead Advisors, LLC	$287.5K	425,600
STATE STREET CORP	$258.9K	383,191
Nuveen, LLC	$250.2K	370,325
AQR CAPITAL MANAGEMENT LLC	$215.5K	318,951
UBS Group AG	$210.7K	311,721

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MYO on your watchlist

Track score changes the day MYOMO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MYO a good stock to buy?

13F Pro's AI-powered analysis of MYOMO, INC. (MYO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MYO are available on the MYO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MYO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MYO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MYOMO, INC.'s investment landscape.